Egge Kjetil H, Barratt-Due Andreas, Nymo Stig, Lindstad Julie K, Pharo Anne, Lau Corinna, Espevik Terje, Thorgersen Ebbe B, Mollnes Tom E
Department of Immunology, Oslo University Hospital Rikshospitalet, and K. G. Jebsen IRC, University of Oslo, Oslo, Norway.
Research Laboratory, Nordland Hospital and Faculty of Health Sciences, K. G. Jebsen TREC, University of Tromsø, Tromsø, Norway.
Clin Exp Immunol. 2015 Sep;181(3):457-67. doi: 10.1111/cei.12645. Epub 2015 Jul 19.
Combined inhibition of complement and CD14 is known to attenuate bacterial-induced inflammation, but the dependency of the bacterial load on this effect is unknown. Thus, we investigated whether the effect of such combined inhibition on Escherichia coli- and Staphylococcus aureus-induced inflammation was preserved during increasing bacterial concentrations. Human whole blood was preincubated with anti-CD14, eculizumab (C5-inhibitor) or compstatin (C3-inhibitor), or combinations thereof. Then heat-inactivated bacteria were added at final concentrations of 5 × 10(4) -1 × 10(8) /ml (E. coli) or 5 × 10(7) -4 × 10(8) /ml (S. aureus). Inflammatory markers were measured using enzyme-linked immunosorbent assay (ELISA), multiplex technology and flow cytometry. Combined inhibition of complement and CD14 significantly (P < 0.05) reduced E. coli-induced interleukin (IL)-6 by 40-92% at all bacterial concentrations. IL-1β, IL-8 and macrophage inflammatory protein (MIP)-1α were significantly (P < 0.05) inhibited by 53-100%, and the effect was lost only at the highest bacterial concentration. Tumour necrosis factor (TNF) and MIP-1β were significantly (P < 0.05) reduced by 80-97% at the lowest bacterial concentration. Monocyte and granulocyte CD11b were significantly (P < 0.05) reduced by 63-91% at all bacterial doses. Lactoferrin was significantly (P < 0.05) attenuated to the level of background activity at the lowest bacterial concentration. Similar effects were observed for S. aureus, but the attenuation was, in general, less pronounced. Compared to E. coli, much higher concentrations of S. aureus were required to induce the same cytokine responses. This study demonstrates generally preserved effects of combined complement and CD14 inhibition on Gram-negative and Gram-positive bacterial-induced inflammation during escalating bacterial load. The implications of these findings for future therapy of sepsis are discussed.
已知联合抑制补体和CD14可减轻细菌诱导的炎症反应,但细菌载量对该效应的依赖性尚不清楚。因此,我们研究了在细菌浓度增加的情况下,这种联合抑制对大肠杆菌和金黄色葡萄球菌诱导的炎症反应的影响是否依然存在。将人全血与抗CD14、依库珠单抗(C5抑制剂)或康普他汀(C3抑制剂)或它们的组合进行预孵育。然后加入热灭活的细菌,最终浓度为5×10⁴ - 1×10⁸/ml(大肠杆菌)或5×10⁷ - 4×10⁸/ml(金黄色葡萄球菌)。使用酶联免疫吸附测定(ELISA)、多重技术和流式细胞术测量炎症标志物。在所有细菌浓度下,联合抑制补体和CD14均显著(P < 0.05)降低大肠杆菌诱导的白细胞介素(IL)-6达40 - 92%。IL-1β、IL-8和巨噬细胞炎性蛋白(MIP)-1α显著(P < 0.05)被抑制53 - 100%,且仅在最高细菌浓度时该效应消失。肿瘤坏死因子(TNF)和MIP-1β在最低细菌浓度时显著(P < 0.05)降低80 - 97%。在所有细菌剂量下,单核细胞和粒细胞CD11b显著(P < 0.05)降低63 - 91%。乳铁蛋白在最低细菌浓度时显著(P < 0.05)减弱至背景活性水平。对金黄色葡萄球菌也观察到类似的效应,但总体而言,这种减弱不太明显。与大肠杆菌相比,需要更高浓度的金黄色葡萄球菌才能诱导相同的细胞因子反应。本研究表明,在细菌载量不断增加的过程中,联合抑制补体和CD14对革兰氏阴性和革兰氏阳性细菌诱导的炎症反应的影响总体上得以保留。讨论了这些发现对未来脓毒症治疗的意义。